Recent advances in HS treatment have seen the emergence of clinical trials with complement directed treatments such as vilobelimab (monoclonal antibody blocking C5a, InflaRx) and Avacopan (C5aR1 inhibitor, ChemoCentryx). This evidence concerns the gene C5 and histiocytic sarcoma.